Last edition
News about "eptinezumab Marketing Authorisation (MA)"
Japan Approves Lundbeck's Vyepti for Migraine Prevention
Lundbeck's Vyepti (eptinezumab) gains Japan approval for migraine prevention, the only IV CGRP-targeted preventive treatment, now in 30+ countries.
Eptinezumab Marketing Authorisation (MA) | 17/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members